Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bridgewater, New Jersey 08807


Purpose:

The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.


Criteria:

Inclusion Criteria: - Diagnosis of metastatic or locally advanced non-hematological cancer - Patients with solid tumors refractory to therapy or for whom no therapy exists Exclusion Criteria: - Five or more prior chemotherapy lines for metastatic disease - Eastern Cooperative Oncology Group (ECOG) performance status >2 - Patients having discontinued previous specific anti-cancer treatment - Patients who have not recovered from all toxic effects from previous specific anti-cancer treatment (excluding alopecia) - Patients with abnormal biological/hematological parameters, cardiac abnormalities or serious infection/intercurrent illness likely to jeopardize the patient's safety or the course of the protocol treatment - No adequate birth control methods The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


NCT ID:

NCT00547261


Primary Contact:

Study Director
ICD CSD
Sanofi-Aventis


Backup Contact:

N/A


Location Contact:

Bridgewater, New Jersey 08807
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.